Синдопа

Quick links to important sections

Синдопа

Treatment option: Parkinson Disease

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Синдопа

Property Description
Active ingredient Levodopa, Carbidopa
Form Tablets (Immediate-release, Extended-release), Capsules, Enteral Suspension
Pharmacological class Dopaminergic antiparkinsonism agents
Common use Addressing chemical deficiency in the central nervous system to improve motor control
Origin Synthetic combination drug

Синдопа (Co-careldopa) is a synthetic, fixed-dose combination drug classified as a dopaminergic antiparkinsonism agent for managing neurological conditions. This medicine belongs to a class of agents that influence the central nervous system to rebalance signaling pathways essential for movement. The combination of two active ingredients makes it an approach for restoring chemical sufficiency.

What Type of Medicine is Синдопа?

The identity of Синдопа is defined by its strategic, synergistic composition of Levodopa and Carbidopa, a formulation known generically as co-careldopa. The primary component, Levodopa, is chemically a prodrug that must cross the blood-brain barrier to be converted into the active compound dopamine. The drug is thus a central nervous system agent. This medicine is administered primarily through oral administration in various formats, including standard immediate-release tablets and specialized extended-release tablets and capsules. The availability of an enteral suspension further highlights an adaptation for continuous, specialized delivery in patients requiring highly consistent drug levels.

What is the Purpose of Combining Levodopa and Carbidopa?

The essential purpose of combining these two substances is to maximize the effective delivery of Levodopa to the brain. Carbidopa is included specifically to prevent the rapid, premature breakdown of Levodopa in the periphery of the body through peripheral DOPA decarboxylase inhibition. This strategic formulation provides a therapeutic advantage by maximizing the central nervous system Levodopa bioavailability. This optimization helps to re-establish the critical chemical signaling, which is the mechanism by which the combination aims to achieve improved motor control and functional capacity, such as aiding in the maintenance of daily activities.

Regulatory References

  1. NIH DailyMed

What side effects are possible with Синдопа?

Possible Side Effects and Safety Information

The safety profile of Co-careldopa (Синдопа) is defined by officially documented adverse reactions, which are classified by frequency and the body system affected, consistent with regulatory standards (e.g., FDA and EMA).

Commonly Documented Adverse Reactions

Adverse reactions classified as Very Common or Common typically involve the Nervous System and Gastrointestinal System. Dyskinesia (abnormal, involuntary movements) is a frequently reported motor complication, often associated with long-term exposure to levodopa. Other common effects include nausea, vomiting, insomnia, hallucinations, and confusion [Table of Commonly Documented Adverse Reactions]. These effects may be more pronounced during the initial phase of treatment or dose adjustment.

Serious and Clinically Significant Safety Concerns

The regulatory profile lists several less common but clinically important effects. These include the development of Neuroleptic Malignant Syndrome (NMS)-like symptoms upon rapid withdrawal or dose reduction, and the emergence of certain Impulse Control/Compulsive Behaviors (e.g., pathological gambling, hypersexuality). Rare reports of serious reactions affecting the Blood and Lymphatic System, such as Haemolytic Anaemia, are also documented.

Official Safety Constraints and Considerations

Official labeling contains specific restrictions. The medication is contraindicated in patients receiving non-selective Monoamine Oxidase Inhibitors (MAOIs) due to the risk of hypertensive crisis, in those with narrow-angle glaucoma, and in patients with a history of malignant melanoma. Caution is advised for older adults, who may be more susceptible to central nervous system effects, and for patients with a history of major psychotic disorder or certain severe organ diseases.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage with Синдопа (Carbidopa/Levodopa) results in severe symptoms associated with excessive central dopaminergic activity, which affects both the central nervous system and the cardiovascular system.

Documented Clinical Manifestations

Official regulatory documents describe several key signs of excess drug exposure:

  • Involuntary Movements (Dyskinesia): A primary manifestation of overdose.
  • Blepharospasm: Cited as a useful early sign of excess dosage in some patients.
  • Mental Disturbances: Including agitation, confusion, insomnia, and anxiety.

Required Emergency Actions

Overdose constitutes a medical emergency. Urgent medical attention must be sought immediately due to the risk of life-threatening complications, particularly cardiac arrhythmias.

The management procedures officially documented in regulatory labels include:

  • Continuous ECG Monitoring: Essential to detect and manage cardiac rhythm disturbances.
  • Symptomatic and Supportive Treatment: General care to maintain vital functions, including establishing an adequate airway and administering intravenous fluids.
  • Gastric Lavage: An officially described procedural step to remove unabsorbed medication.
  • No Specific Antidote: Regulatory sources confirm that no specific antidote is known, and Pyridoxine (Vitamin B6) is ineffective in reversing the effects.

Therapeutic Uses of Синдопа

Quick Facts

  • Primary Use: Management of Parkinson's disease symptoms
  • Associated Conditions: Used to address parkinsonism that follows carbon monoxide or manganese intoxication
  • Key Benefit: Helps to manage motor symptoms like rigidity, slowness of movement (bradykinesia), and tremor

Therapeutic Overview

Синдопа (Carbidopa/Levodopa) is a therapeutic agent indicated for the management of the signs and characteristics associated with Parkinson's disease. The therapeutic goal of treatment is to offer relief from several of the characteristic motor symptoms that affect daily functioning.

This medication is commonly utilized to address symptoms of parkinsonism, including muscle stiffness (rigidity), resting tremor, and the general slowing of movement. It is often a key component of a treatment regimen and is considered a standard approach for helping to manage these motor difficulties.

Additionally, the combination of Carbidopa and Levodopa is used to treat parkinsonism arising from other specific causes, such as conditions that follow carbon monoxide poisoning or manganese intoxication. The treatment is intended to improve motor control, which may contribute to enhanced ability to perform routine activities.

Eligibility and Restrictions for Use

The eligibility to use Синдопа (Carbidopa/Levodopa) is strictly defined by regulatory documents, allowing its use primarily in adult patients with Parkinson's disease and related parkinsonism.

Populations for whom use is Contraindicated

The medicine is contraindicated and must not be used by individuals with a known hypersensitivity to any component of the drug, patients with narrow-angle glaucoma, or those with a history of melanoma or undiagnosed skin lesions. Use is also prohibited for patients currently taking or having recently taken (within two weeks) a nonselective MAO inhibitor.

Age- and Condition-Based Restrictions

Age-related eligibility rules indicate that use is not recommended for the pediatric population (under 18 years) as its safety and efficacy have not been established. The drug is contraindicated in severe hepatic impairment (liver problems). Conditional use is required for patients with renal impairment or milder liver impairment.

Pregnancy and Lactation

Use is generally not recommended during pregnancy unless the therapeutic benefits are deemed to outweigh the potential fetal risks. During lactation, a regulatory decision is required to either discontinue the drug or discontinue breastfeeding.

What should I know about interactions with other medicines?

The official regulatory documents for Levodopa/Carbidopa (Синдопа) establish specific interaction constraints related to pharmacokinetic and pharmacodynamic effects, as well as mandatory prohibitions for co-administration.

Formal Contraindications and Prohibitions

Interacting Substance/Condition Regulatory Constraint Interaction Mechanism Type
Nonselective MAO Inhibitors Co-administration is contraindicated. Must be discontinued for at least two weeks before starting therapy. Pharmacodynamic
Dopamine-Depleting Agents Use with these substances (e.g., Reserpine, Tetrabenazine) is not recommended. Pharmacodynamic
Narrow-Angle Glaucoma A condition listed as a formal contraindication in the drug label. Condition-Related

Exposure and Effect Alterations

Co-administration with certain products requires consideration of documented influence on drug exposure and therapeutic efficacy. Iron salts and supplements may reduce the oral bioavailability of Levodopa/Carbidopa, specifically lowering the AUC and C max due to absorption interference. A high-protein diet may similarly impair levodopa absorption by competing for transport across the gut wall.

Certain pharmacodynamic agents may reduce the drug's intended action. Dopamine D2 receptor antagonists (e.g., Phenothiazines) may antagonize the effects of levodopa, diminishing the therapeutic response. The beneficial effects have also been reported to be reversed by substances such as Phenytoin, Papaverine, and Isoniazid. When used with Antihypertensive Agents, there is a documented risk of promoting postural hypotension. The medicine must not be taken with alcohol in the case of specific extended-release formulations.

Mechanism of Action

How Синдопа Works — Mechanism of Action

️ Strategic Protection for Central Neurotransmitter Precursor

The mechanism begins with Carbidopa acting as an irreversible inhibitor of the enzyme Aromatic L-Amino Acid Decarboxylase (AADC) in the body's peripheral tissues. Since Carbidopa cannot cross the Blood-Brain Barrier (BBB), this peripheral action strategically prevents the premature breakdown of Levodopa outside the brain. This action increases the amount of intact Levodopa available in the bloodstream for transport into the Central Nervous System (CNS).


Replenishment of Dopaminergic Signaling

Once Levodopa enters the CNS, it is absorbed by the remaining dopaminergic neurons and rapidly converted into the active neurotransmitter dopamine by the available AADC enzyme. This synthesized dopamine then functions as an agonist, activating the postsynaptic Dopamine Receptors in the corpus striatum. This action provides a targeted increase in dopamine activity, which results in the modulation of neural circuits involved in motor command processing.


Constraints on Central Delivery

The mechanism’s efficacy is inherently constrained by the process of Levodopa transport across the BBB, which relies on the competitive Large Neutral Amino Acid Transporter (LNAAT). Furthermore, the ability to create dopamine is entirely dependent on the presence of functional, remaining AADC-containing neurons within the brain. These physiological limitations dictate the ultimate intensity of the striatal dopaminergic activity that the mechanism can produce.

Dosage and Administration Information

How Синдопа is Used

The administration of Синдопа (Carbidopa/Levodopa) is determined by its available dosage forms. The primary methods of administration include oral intake for the immediate-release (IR) and extended-release (ER) tablets and capsules, and specialized enteral (jejunal) infusion for the liquid suspension.

Treatment typically begins with a gradual dose titration initiated from a standard adult starting dose, such as 25 mg Carbidopa and 100 mg Levodopa, administered three times daily. The dosage is incrementally adjusted at defined intervals until the optimal individual response is achieved, though the total daily intake of the Carbidopa component often does not exceed 200 mg.

Key Administration Instructions

Usage Parameter Instruction
Dosing Frequency Administered multiple times daily (IR/ER) or as a continuous infusion over a 16-hour waking cycle (suspension).
Food Relationship May be taken with or without food, but high-protein or high-fat meals can delay or diminish Levodopa absorption.
Physical Handling Extended-release tablets and capsules must be swallowed whole to preserve their controlled-release characteristics; they should not be crushed or chewed.
Procedural Constraint Levodopa monotherapy must be discontinued for a minimum of 12 hours before starting this combination product.
Special Populations Use is not recommended for pediatric patients under 18 years of age.

These protocols are used to ensure the medicine is delivered consistently, necessitating that dosage increases occur only after appropriate titration periods and that abrupt cessation is avoided.

Recent Clinical Evidence

Research evidence / Overview of studies for Синдопа (Carbidopa/Levodopa)


Evidence for Use in Managing Core Motor Symptoms

The foundation of research for this combination is built upon a large volume of Randomized Controlled Trials (RCTs). These studies were applied in research contexts involving fluctuating or unstable symptoms, examining patient groups with early and established Parkinson's disease. Researchers monitored outcomes related to physical discomfort and daily functioning or activity level. Research findings were tracked by measuring changes in standardized rating scales for motor symptoms and assessing the ability of participants to perform common Activities of Daily Living (ADLs).

The studies report how symptoms evolved in the observed populations receiving the medication, often compared against a placebo. Research highlights changes measured during the study period related to daily functioning, and the data show patterns related to symptom scale scores across the groups studied. This evidence contributes to understanding the patterns of motor and functional outcomes in individuals involved in this research.


Studies on Managing Motor Fluctuations

For patients in the advanced stages of the condition who who experience motor fluctuations, the focus of research shifts to the delivery method. Studies explored continuous infusion systems, such as enteral suspensions, and specialized extended-release formulations. These trials were applied in research contexts involving fluctuating or unstable symptoms, with a specific focus on outcomes capturing phases of heightened symptom activity, known as "off" time.

These studies monitored the total daily duration of time spent in the highly symptomatic "off" state, and the total time in the "on" state. Studies reported measurements showing patterns in the duration of these phases when comparing the different delivery systems. However, some scientific reviews exploring this research noted that findings were mixed or showed variability across studies, particularly when trying to compare all continuous delivery strategies directly. Research provides insight into short-term changes, but the evidence quality varies across studies when describing observed outcomes.


Long-Term Evidence and Follow-up Durations

Research has examined outcomes in cohorts using the medication over defined time intervals. Follow-up durations in key clinical trials and long-term extensions typically range from a few months up to several years. Some comprehensive studies have followed participants for as long as five years to observe patterns related to the evolution of symptoms over an extended period.

While mid-term data are available, research highlights changes measured during the study period, but there is limited information for long-term outcomes for periods extending significantly beyond five years. The progressive nature of the condition means that follow-up durations were limited for comprehensive long-term observations.


What is Still Uncertain in the Research Landscape

Some studies report inconsistencies or heterogeneity in findings when comparing all available controlled delivery systems for managing fluctuations. Additionally, there is limited information for long-term outcomes for periods extending past five years, as the progression of the underlying condition often requires further adjustment of management strategies. The results apply only to the populations studied, and data for certain groups remain insufficient. These factors contribute to the broader evidence landscape, but also highlight areas where further study is needed.

Key Studies & References

  1. NICE Guideline NG71: Parkinson's disease in adults

Frequently Asked Questions (FAQ)

Common questions about Синдопа (FAQ)

Q: Can Syndopa be combined with alcohol intake?

Official warnings advise that alcohol may increase certain central nervous system effects of the medicine, such as potential impairment of judgment or thinking. For this reason, official warnings advise that caution is warranted, and the use of alcohol is generally discouraged during treatment.

Q: Is it true that Syndopa affects mood or emotions?

Official documents describe potential effects on mood and behavior, as the medication influences the central nervous system. These documented effects include reports of anxiety, nervousness, confusion, hallucinations, irritability, and the worsening of depression.

Q: Are there any dietary restrictions when taking Syndopa?

Yes, official product information notes that high-protein or high-fat meals can potentially delay or diminish the absorption of the Levodopa component of the medicine. Official regulatory information describes that maintaining a consistent daily protein intake may help minimize competition with the drug's absorption.

Q: Does Syndopa help with resting tremor?

The medication is officially indicated for the treatment of symptoms associated with Parkinson's disease. The therapeutic goal is to restore chemical sufficiency in the brain to improve motor control and functional capacity, which includes addressing key symptoms like tremor.

Q: What is the 'half-life' of Syndopa, simply put?

The term 'half-life' refers to the amount of time required for the concentration of the medicine in the body to be reduced by half. For the immediate-release formulation, the half-life of the Levodopa component is described as being approximately 90 minutes.

Q: Can Syndopa affect vision?

Official safety information describes the potential for effects on vision. This includes rare reports of blurred vision, sudden eye pain, or seeing halos around lights.

Q: What is the difference between taking Syndopa at the beginning versus the end of a meal?

Official instructions state that the medicine may be taken with or without food. The main consideration is that the type of meal (high-protein/high-fat) can delay or diminish absorption, regardless of when it is consumed relative to the mealtime.

Q: Can Syndopa be taken if you already take vitamins?

Official information indicates that iron salts or supplements may reduce the absorption of the drug. Vitamin B6 (Pyridoxine) is also addressed, noting that it may reduce the effectiveness of Levodopa unless sufficient Carbidopa is present in the medication.

Q: How long after starting Syndopa can changes be noticed?

Official pharmacokinetic data indicates that the effects of the immediate-release formulation can begin as early as 20 to 50 minutes after taking a dose. The time required to observe optimal effects can vary between individuals, often requiring a period of dose adjustment.

Q: Can Syndopa cause severe drowsiness or dizziness?

Drowsiness (somnolence) and dizziness are described in the official safety information as common adverse reactions. Regulatory warnings also advise that, very rarely, episodes of sudden onset of sleep without warning have been reported with this class of medication.

Q: What should I do if I missed a dose of Syndopa?

Official administration guidelines emphasize the importance of regular, consistent dosing. If a dose is missed, the recommended course of action for resuming treatment is typically described in the product information as taking the next scheduled dose at the usual time.

Q: Why do some people say Syndopa stops helping over time?

Regulatory literature acknowledges that as the underlying condition progresses, patients may experience motor fluctuations or periods of heightened symptoms. These fluctuations, sometimes described as 'off' time, can lead to a perceived reduction in the medicine's effectiveness.

Q: Does Syndopa affect the ability to drive a car?

Due to potential side effects such as drowsiness and rare episodes of sudden sleep onset, official warnings advise that caution should be exercised regarding the ability to drive or operate machinery. Patients should be aware of these potential effects before driving or engaging in hazardous activities.

Q: How often should I have tests when treated with Syndopa?

Official guidelines recommend periodic evaluations during extended therapy. These evaluations often include checks of hepatic (liver), hematopoietic (blood), cardiovascular, and renal (kidney) function.

Q: Does Syndopa cause habituation or dependence?

Official labeling documents state that rapid withdrawal or dose reduction may result in a severe, sudden clinical phenomenon, necessitating caution.

Q: Does taking Syndopa affect blood pressure?

Official safety information indicates that postural hypotension (low blood pressure when changing position) is a potential adverse reaction. Hypertension (high blood pressure) has also been reported in rare instances.

Q: Are interactions between Syndopa and herbal supplements described?

Official information indicates that certain herbal products, such as Kava or St. John’s Wort, may affect how the medication works.

Q: Can Syndopa be taken if there are stomach problems?

Caution is generally advised in regulatory documents for patients with a history of certain severe organ diseases. While nausea and vomiting are commonly documented side effects, the official information does not list common stomach problems as a contraindication.

Q: Why can the color of urine or sweat change when taking Syndopa?

Official labeling informs patients that the medicine can cause the color of saliva, sweat, or urine to change. This is a common and described effect, often resulting in a dark red, brown, or black color.

Q: Is there a risk of falling when taking Syndopa?

Because adverse reactions such as dizziness and postural hypotension (a drop in blood pressure upon standing) are reported, there is a possibility that these effects could impact balance.

Q: Does stress affect the effectiveness of Syndopa?

Some research has explored how acute cognitive stress may influence the effects of the medication on certain symptoms. These studies suggest that the effectiveness of the medicine may be modulated by the presence of stress.

Q: What should I do if I experience nausea when taking Syndopa?

Nausea is a commonly documented side effect. Official patient literature sometimes describes that taking the medication with a low-protein snack may help reduce this effect.

How should Синдопа be stored and disposed of?

How to Store and Dispose of Синдопа?

Carbidopa/Levodopa tablets must be stored and disposed of strictly according to official regulatory labeling to maintain stability and ensure safety.

Storage Requirements

The medicine requires storage at 25 C (77 F), with controlled temperature excursions permitted between 15 C and 30 C (59 F and 86 F). The product must be actively protected from light and moisture and stored in a tightly closed, light-resistant container. Certain formulations require storage below 25 C in the original package. Crucially, the medicine must be kept out of the sight and reach of children.

Disposal Requirements

Unused or expired Синдопа must not be thrown away via wastewater or household waste. Disposal must strictly adhere to local regulations for pharmaceutical waste, as instructed by regulatory authorities.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Синдопа found in:

A-Z Index: